INDIGO Biosciences

INDIGO Biosciences specializes in advanced in vitro assay solutions, offering cell-based luciferase reporter assay kits for various human receptors, facilitating drug discovery and development for research institutions and pharmaceutical companies worldwide. Founded in 2005 in State College, US, INDIGO Biosciences focuses on providing innovative assay solutions. The company successfully secured funding in a Series B round, raising USD 0. 5 mn from Allied Growth Strategies & Management and Life Sciences Greenhouse of Central Pennsylvania in June 2016.

The CEO is Fred Marroni, with Blake Peterson as the founder. INDIGO Biosciences specializes in providing advanced in vitro assay solutions, primarily focusing on cell-based luciferase reporter assay kits that target various human receptors. Their offerings include kits for the Human Glucagon-Like Peptide-1 Receptor (GLP-1R), Human Fibroblast Growth Factor Receptor 3 (FGFR3), Human Dopamine Receptor D1 (DRD1), Human Glucagon Receptor (GCGR), and Human Gastric Inhibitory Polypeptide Receptor (GIPR). These kits help in screening test samples to measure functional activity against their respective receptors, aiding researchers in drug discovery.

Their products ensure clear, reproducible results and exceptional cell viability, serving a clientele that includes pharmaceutical companies, biotech firms, and academic institutions across North America, Europe, and parts of Asia. INDIGO Biosciences generates revenue through the sale of its specialized assay kits and services, primarily operating in a B2B model. Clients order these kits directly for research applications, often through one-time purchases with volume discounts. The company also provides pre-clinical non-GLP Lead Discovery and Optimization services, enhancing revenue by offering tailored scientific consultation.

Their flagship product, the GLP-1R Reporter Assay Kit, supports researchers with a comprehensive package tailored to their needs in the biotechnology and pharmaceutical sectors. INDIGO Biosciences plans to leverage its recent Series B funding of USD 0. 5 mn for future product development and market expansion. The company aims to introduce new assay kits targeting additional receptors by mid-2023, enhancing its product line.

Additionally, INDIGO is focusing on expanding into European and Asian markets by late 2024 to increase its global footprint. The funding will support these initiatives, enhancing both product offerings and market reach.